Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) ConferenceGlobeNewsWire · 3 days ago
Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026GlobeNewsWire · 6 days ago
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's DayZacks Investment Research · Sep 21, 2026
Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day TranscriptSeeking Alpha · Sep 16, 2026
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026GlobeNewsWire · Sep 10, 2026
Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeeking Alpha · Sep 10, 2026Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.36 | -$0.45 | Miss |
| May 12, 2026 | -$0.40 | -$0.33 | Beat |
| Mar 26, 2026 | -$0.50 | -$0.41 | Beat |
| Nov 12, 2025 | -$0.63 | -$0.44 | Beat |
| Aug 12, 2025 | -$0.54 | -$0.68 | Miss |
| May 13, 2025 | -$0.56 | -$0.48 | Beat |